 |
|
|
|
|
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Progenics Pharmaceuticals Inc.
| | | | | Phone: | (914) 789-2800 | | Fax: | (914) 789-2817 | | Year Established: | 1986 | | Employees: | 77 | | Ticker: | PGNX | | Exchange: | NASDAQ | | Main Contact: | Richard W. Krawiec, Ph.D., VP, Corporate Affairs | | | | Other Contacts: | Bryce V. Tenbarge, VP of Commercial
Patrick Fabbio, CFO
Tage Ramakrishna M.D., VP, Clinical Research
Ann Marie Assumma M.S., VP, Regulatory Affairs
Benedict Osorio M.B.A., Senior VP, Quality
Vivien Wong Ph.D., Senior VP, Product Development
Robert J. Israel M.D., Senior VP, Medical Affairs
Hagop Youssoufian, MD, Executive VP, R&D
Mark R. Baker J.D., CEO
Robert A. McKinney CPA, Senior VP, Finance and Operations & CFP & Treasurer
| | | | Company Description | | Progenics Pharmaceuticals is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) subcutaneous injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Regulatory approval is pending for use of RELISTOR in patients with chronic, non-cancer pain. | |
|
|
|
|
|
|
|
